Alnylam Pharmaceuticals valuation

ALNY · NASDAQ · USD

Compare Alnylam Pharmaceuticals
$156.50Change from previous close: −2.02%Absolute change: −$3.23

Close · November 17, 2026

Valuation

The P/E ratio is 8.34. The average price target of 27 analysts is $299.96.

Data as of November 15, 2026

Alnylam Pharmaceuticals compared with similar companies

Alnylam Pharmaceuticals's P/E (trailing 12 months): 8.34, −71% against the median of a group of 6 similar companies (29.2).

Alnylam Pharmaceuticals's metrics compared with similar companies
MetricAlnylam PharmaceuticalsMedian25th–75th percentileBand
P/E (trailing 12 months)8.3429.218.6 – 55.3Low
Forward P/E15.215.211.5 – 19.3Middle
EV/EBITDA20.813.410.5 – 19.4High
Price/book6.138.034.77 – 14.3Middle
Price/sales4.418.144.95 – 15.9Low
Gross margin77.3%77.3%66.1% – 91.5%Middle
Operating margin19.5%19.5%-48.6% – 31.6%Middle
Net margin52.8%4.4%-19.9% – 30.2%High
ROE138.1%7.8%-8.3% – 88.3%High
Debt/equity0.830.300.02 – 0.92Middle

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Other metrics

Valuation multiples

Market cap
$22.11B
Enterprise value
$21.51B
PEG
0.22
EV/revenue
4.29

Profitability and growth

ROA
9.5%
ROIC
17.0%
Revenue growth (year over year)
16.7%
Earnings growth (year over year)
633.5%

Financial health

Total cash
$3.59B
Total debt
$3B
Current ratio
2.48
Quick ratio
2.27
Altman Z-Score
6.83
Piotroski F-Score
5.00

Dividends

Dividend yield
0.0%
Payout ratio
0.0%

Analysts and estimates

Average price target
$299.96
Median price target
$299.00
High price target
$455.00
Low price target
$180.00
Analysts with a price target
27
Consensus
Buy
Forward EPS
$10.83
EPS estimate, current year
$22.68

Shares and trading

Beta
0.44
Average volume
2.05M
Shares outstanding
133.94M
Float
133.62M
Institutional ownership
101.6%
Insider ownership
0.5%
Short interest (% of float)
5.4%
Short ratio (days)
2.61